Boris Pasche

List of Publications by Year
in descending order

33 papers	1,392 citations	394421 19 h-index	414414 32 g-index
34 all docs	34 docs citations	34 times ranked	2352 citing authors

#	Article	IF	Citations
1	Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncology, 2018, 4, 1691.	7.1	190
2	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncology, The, 2017, 18, 770-778.	10.7	167
3	Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis. Molecular Cell, 2020, 80, 263-278.e7.	9.7	120
4	Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. Journal of Experimental and Clinical Cancer Research, 2009, 28, 51.	8.6	104
5	Dissecting intratumoral myeloid cell plasticity by single cell RNAâ€seq. Cancer Medicine, 2019, 8, 3072-3085.	2.8	103
6	Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Research, 2016, 76, 4970-4980.	0.9	102
7	Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells. Nature Immunology, 2018, 19, 29-40.	14.5	97
8	TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene, 2020, 39, 64-78.	5.9	64
9	Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chinese Journal of Cancer, 2013, 32, 573-581.	4.9	49
10	Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. EBioMedicine, 2019, 44, 194-208.	6.1	45
11	IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Letters, 2021, 500, 132-146.	7.2	42
12	Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer. Cancer Research, 2021, 81, 3358-3373.	0.9	32
13	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics, 2017, 7, 2914-2923.	10.0	31
14	Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2â€ T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine, 2019, 44, 209-224.	6.1	31
15	Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 168-174.	0.6	29
16	Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Frontiers in Oncology, 2020, 10, 615472.	2.8	29
17	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Journal of Hematology and Oncology, 2017, 10, 100.	17.0	28
18	Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Molecular Cancer, 2018, 17, 81.	19.2	27

#	Article	IF	Citations
19	Use of non-ionizing electromagnetic fields for the treatment of cancer. Frontiers in Bioscience - Landmark, 2018, 23, 284-297.	3.0	22
20	Clinical Outcomes of Upfront Stereotactic Radiosurgery Alone for Patients With 5 to 15 Brain Metastases. Neurosurgery, 2019, 85, 257-263.	1.1	19
21	A tale of three subspecialties: Diagnosis recording patterns are internally consistent but Specialty-Dependent. JAMIA Open, 2019, 2, 369-377.	2.0	11
22	Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. International Journal of Biological Markers, 2019, 34, 90-97.	1.8	10
23	Lynch Syndrome Testing. JAMA - Journal of the American Medical Association, 2016, 316, 38.	7.4	7
24	Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. Molecular Cancer Therapeutics, 2021, 20, 553-563.	4.1	7
25	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist, 2021, 26, 610-618.	3.7	5
26	Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. Journal of Radiosurgery and SBRT, 2018, 5, 277-283.	0.2	5
27	CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Scientific Reports, 2019, 9, 14385.	3.3	4
28	Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus, 2021, 13, e12574.	0.5	4
29	An HF exposure system for mice with improved efficiency. Bioelectromagnetics, 2016, 37, 223-233.	1.6	3
30	Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates. Frontiers in Oncology, 2021, 11, 584896.	2.8	3
31	Comments on â€˜Search for tumor-specific frequencies of amplitude modulated 27â€‰MHz electromagnetic fields in mice with hepatocarcinoma xenografted tumorsâ€™. International Journal of Radiation Biology, 2020, 96, 845-846.	1.8	1
32	Initiative on #4openScienceStandsForUkraine scientists and students. 4open, 2022, 5, E2.	0.4	1
33	EXTH-41. THE ANTI-PROLIFERATIVE EFFECTS OF RF EMF AMPLITUDE-MODULATED (AM RF EMF) AT TUMOR SPECIFIC FREQUENCIES ON GLIOBLASTOMA CELLS. Neuro-Oncology, 2016, 18, vi68-vi68.	1.2	0